** Shares of weight management services provider WW
International WW.O rise 7.35% to $10.66 premarket
** Morgan Stanley upgrades to "overweight" from
"equal-weight", raises PT to $13 from $5
** Brokerage notes co's acquisition of GLP-1 obesity drug
telehealth platform Sequence should be enough to offset declines
in core business
** "The key tenet of the GLP-1 obesity drug bull case is
WW's ability to leverage its brand and lapsed member base to
drive low cost Sequence subscriber growth" - MS
** "Although it remains early, we are seeing encouraging
signs the bull case is beginning to play out as Sequence has
tripled its market share of free web traffic to GLP-1 telehealth
players post-acquisition" - MS
** Notes that the near-term catalyst path is one of the most
robust across its coverage, and sees many events that could
support Bull case over the next six months
** As of last close, stock had more than doubled in value
since the start of the year
(Reporting by Shashwat Chauhan in Bengaluru)
((Shashwat.Chauhan@thomsonreuters.com;))